Bimini Biotech

Executive Summary

Bimini Biotech is a Leiden-based preclinical biotechnology company developing first-in-class small-molecule therapeutics targeting the Wiskott-Aldrich Syndrome protein (WASp) for oncology and autoimmune diseases. Founded in 2018, the company's pipeline includes both WASp agonists and antagonists, aiming to modulate immune cell actin dynamics. With no disclosed funding or partnerships, Bimini operates in a niche but biologically validated target space. The company's progress to date remains limited to preclinical studies, and its ability to advance toward clinical trials will depend on securing financing and generating compelling in vivo efficacy data. The WASp pathway offers potential differentiation in immuno-oncology and autoimmunity, but the early stage and lack of public data warrant a cautious conviction score.

Upcoming Catalysts (preview)

• Q4 2026Preclinical efficacy data release (WASp agonist in oncology)60% success
• Q2 2027Series A financing round50% success
• Q3 2027Partnership or licensing deal for WASp antagonist program30% success